Ken Griffin Altimmune, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $216,700 - $319,140	39,400 Added 14.8%	305,700 $1.88 Million
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $291,954 - $505,362	-49,400 Reduced 15.65%	266,300 $1.77 Million
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $584,442 - $981,891	71,100 Added 29.07%	315,700 $3.21 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $276,702 - $1.5 Million	129,300 Added 112.14%	244,600 $2.75 Million
Q3 2023 Nov 14, 2023	BUY	$2.4 - $3.45 $28,320 - $40,710	11,800 Added 11.4%	115,300 $299,000
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $588,915 - $1.02 Million	-170,700 Reduced 62.25%	103,500 $365,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $393,022 - $1.58 Million	93,800 Added 52.0%	274,200 $1.16 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $884,488 - $1.66 Million	-101,200 Reduced 35.94%	180,400 $2.97 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.11 Million - $2.33 Million	104,000 Added 58.56%	281,600 $3.6 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.